It is an AI platform that can autonomously execute tasks in a workflow, such as analyzing single-cell data and human genetics for drug discovery.

How does this partnership affect Chugai's financial outlook?

Analysts see fair value at ¥9,687, a 38% upside. Optimists model sales near ¥1.935 trillion and profit around ¥810 billion by 2029.

AI in HealthcareTop Companies' AI MovesAI Business & IndustryTop Companies AIAug 29, 2026Aug 30, 2026, 06:32 JST

Chugai and Phylo partner on agentic AI

Send on LINE

3 Key Points

What happened
Chugai Pharmaceutical began rolling out an agentic AI platform across its drug discovery workflow and partnered with Phylo to apply the technology to single-cell data, human genetics, and disease biology.
Why it matters
The move leverages Chugai's solid profitability to fund AI-driven R&D, aiming for earlier and more precise target selection. It addresses short-term concerns about R&D productivity and diversification, but its impact on sales dependence on Hemlibra and Actemra remains unclear and does not materially change near-term patent or pricing risks.
What to watch
A consensus forecast sees fair value at ¥9,687, implying 38% upside from the current price. More optimistic analysts already model sales near ¥1.935 trillion and profit around ¥810 billion by 2029, before the Phylo deal.

Not sure about something? Ask the AI

Questions and answers are published on this page.

Summaries like this, in your inbox every morning.

Get news like this every morning, free

Context & Analysis

Chugai's partnership with Phylo comes as the company faces maturation of its key products. By embedding agentic AI into discovery, Chugai aims to build a stronger pipeline before patents expire. The deal aligns with recent regulatory filings for Tecentriq and Enspryng expansions, linking AI research to late-stage assets. However, the near-term sales concentration in Hemlibra and Actemra remains a risk, and the AI push does not address pricing pressure. Investor expectations vary widely, with fair value estimates ranging from about ¥7,200 to ¥9,687, showing divergent views on AI's impact.

FAQ

What is agentic AI?: It is an AI platform that can autonomously execute tasks in a workflow, such as analyzing single-cell data and human genetics for drug discovery.
How does this partnership affect Chugai's financial outlook?: Analysts see fair value at ¥9,687, a 38% upside. Optimists model sales near ¥1.935 trillion and profit around ¥810 billion by 2029.

AI news that matters for your work, delivered every morning.

Pick your industry and the AI tools you use, and get news related to your work every day.

Get it free

Free · 30 seconds with Google · unsubscribe anytimeWhat is AIToday? →

Ask AI

Ask AI anything about this article. The AI reads this article, earlier AIToday articles, and Wikipedia, and cites its sources. Q&As are published on this page for other readers too.